Abstract
Patients with malignant neoplasms are characterized by a high risk of thrombotic complications, which could complicate antitumor treatment and worsen the survival rate. Changes in the hemostatic system, caused by both the tumor and the treatment methods have the main role in the pathogenesis of thrombotic complications in cancer patients. Low molecular weight heparins are the basis for specific prevention of thromboembolic complications in cancer patients. The use of low molecular weight heparins before and after surgery and chemotherapy reduces the activation of intravascular coagulation, reduces the incidence of venous thrombosis and prevent fatal pulmonary embolism, which enhances the antitumor treatment and improves the quality of life in cancer patients.
Highlights
The main role in pathogenesis of thrombotic complication in cancer patients is changes in the hemostatic sistem caused by the tumor itself as well as methods of treatment
Low molecular weight heparins are the basis of specific prevention of thromboembolic complications in oncological patients
В группе больных опухолями опорно-двигательного аппарата, не получавших медикаментозной профилактики, тромботические осложнения развились у 4 (13%) больных, в группе больных, получавших клексан – у 1 (2%) больного
Summary
Для онкологических больных характерен высокий риск развития тромботических осложнений, в том числе тромбозов глубоких вен и тромбоэмболии легочной артерии. Современные исследования свидетельствуют, что постоянная активация свертывания крови – не только фактор риска развития тромбоза и тромбоэмболии легочной артерии, но и показатель агрессивности опухоли [13,14]. В крупных контролируемых исследованиях было показано увеличение риска венозных тромбоэмболических осложнений в 2–6 раз у больных, получающих химиотерапию [19].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
